Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
| Line item | SIX MONTHS ENDED JUNE 30, 2026 | SIX MONTHS ENDED JUNE 30, 2025 |
|---|---|---|
| Operating lease right-of-use asset and lease liabilities, net | 241 | 21 |
| Net cash used in operating activities | (41,305) | (42,824) |
| Investing activities: | ||
| Purchases of property and equipment | (657) | (1,566) |
| Purchases of investments | (6,442) | (24,591) |
| Maturities of investments | 40,000 | 57,250 |
| Net cash provided by investing activities | 32,901 | 31,093 |
| Financing activities: |
Item 1. Financial Statements
FAQ
- What is Artiva Biotherapeutics, Inc.'s capex?
- Artiva Biotherapeutics, Inc. (ARTV) reported capex of $415K in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s capex changed year-over-year?
- Artiva Biotherapeutics, Inc.'s capex decreased by 60.7% year-over-year, from $1.06M to $415K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Artiva Biotherapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude